RxDoctor Payments Data

Alexander Jenik, PA

Medical · Colorado Springs, CONPI 1891338646

Payments from drug & device makers

$4,396in general payments, 2019–2025

Across 212 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$596
  • AstraZeneca$489
  • Novo Nordisk$458
  • Pfizer$375
  • Amgen$321
  • GSK$200
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,396 in reported general payments places this provider in the 85th percentile of 766 medical providers in Colorado.

See all medical providers in Colorado

Medicare billing

Part B allowed, 2024
$54,454
Medicare patients
128
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$48,417
TrulicityDulaglutide41$42,894
JanuviaSitagliptin Phosphate11$17,226
MyrbetriqMirabegron12$16,786
FarxigaDapagliflozin Propanediol14$15,377
ZenpepLipase/Protease/Amylase11$9,145
Breo ElliptaFluticasone/Vilanterol13$7,874
LinzessLinaclotide13$7,284
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$4,449
Atorvastatin Calcium186$1,892
Omeprazole90$1,795
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,689
Tamsulosin Hcl90$1,520
Pregabalin25$1,300
Levothyroxine Sodium137$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$458$48,41743 claims
Lilly USA, LLCTrulicity$116$42,89441 claims
MerckJanuvia$73$17,22611 claims
Astellas Pharma US IncMyrbetriq$118$16,78612 claims
AstraZenecaFarxiga$489$15,37714 claims
Aimmune Therapeutics, Inc.Zenpep$68$9,14511 claims
GSKBreo Ellipta$200$7,87413 claims
AbbVieLinzess$596$7,28413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 766 medical providers in Colorado.

Other medical in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →